title: Long-term treatment with ximelagatran, an oral direct thrombin inhibitor, persistently reduces the coagulation activity after a myocardial infarction.
abstract: BACKGROUND
  In the ESTEEM study, patients with a recent myocardial infarction were treated with aspirin and randomized to one of four doses (24-60 mg b.i.d) of the oral direct thrombin inhibitor ximelagatran or placebo for 6 months. Ximelagatran and aspirin reduced the risk of recurrent ischemic events compared with aspirin alone. In the present substudy we evaluated the different doses of ximelagatran on pharmacokinetics as measured by plasma concentration of the active compound melagatran and activated partial thromboplastin time (APTT) and pharmacodynamics as related by markers for coagulation activity, prothrombin fragment 1 + 2 (F1 + 2) and D-dimer.
  
  
  RESULTS
  Plasma samples from 518 patients were collected before, during and after the treatment period. There was a linear dose-concentration relation at peak and trough and a linear relation between concentration and APTT (P < 0.001). F1 + 2 and D-dimer were decreased by 25% and 52% at 1 week (P < 0.001) in the ximelagatran groups compared with the placebo group and the reductions were maintained during the 6 months treatment. There were no differences detected in F1 + 2 or D-dimer levels between the different ximelagatran dosages. There was no correlation between the melagatran concentration and the change in F1 + 2 and D-dimer levels. After cessation of ximelagatran F1 + 2 and D-dimer levels returned to the initial levels.
  
  
  CONCLUSIONS
  The dose of ximelagatran and APTT are linearly related to the plasma concentration of melagatran. Ximelagatran induces a sustained and stable reduction of thrombin generation and fibrin turnover without any relation to dose above 24 mg b.i.d. These properties indicate that long-term treatment with a low dose of ximelagatran may provide valuable depression of coagulation activity in aspirin treated post myocardial infarction patients.
authors.affiliation: Department of Cardiology, Uppsala University Hospital, Uppsala, Sweden. christina.christersson@akademiska.se
authors.forename: C
authors.initials: C
authors.lastname: Christersson
authors.forename: J
authors.initials: J
authors.lastname: Oldgren
authors.forename: A
authors.initials: A
authors.lastname: Bylock
authors.forename: L
authors.initials: L
authors.lastname: Wallentin
authors.forename: A
authors.initials: A
authors.lastname: Siegbahn
mesh_terms: D000368:Aged; D001384:Azetidines / Q000008:administration & dosage / Q000493:pharmacokinetics*; D001596:Benzylamines; D015415:Biomarkers / Q000097:blood; D001777:Blood Coagulation / Q000187:drug effects*; D004305:Dose-Response Relationship, Drug; D005260:Female; D005337:Fibrin / Q000378:metabolism; D005998:Glycine / Q000031:analogs & derivatives / Q000097:blood; D006801:Humans; D008297:Male; D009203:Myocardial Infarction / Q000097:blood / Q000188:drug therapy*; D010314:Partial Thromboplastin Time; D010599:Pharmacokinetics; D013917:Thrombin / Q000037:antagonists & inhibitors / Q000096:biosynthesis; D013997:Time Factors
chemical_list: D001384:Azetidines; D001596:Benzylamines; D015415:Biomarkers; C109573:melagatran; C426686:ximelagatran; D005337:Fibrin; D013917:Thrombin; D005998:Glycine